Study S000405

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT02527200
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 56
Start: 2015-11-09
Primary completion: 2020-11-04
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2014-004415-37; OTHER:U1111-1162-7884; OTHER:NL54145.078.15; NIH:2014

Registered primary outcomes

Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks [Week 0, Week 16]
Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks [Week 0, Week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021634	Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. Diene G, The Journal of clinical endocrinology and metabolism	2022	Randomized trial	PMID 36181471 DOI	registry reference RESULT:36181471